(GMDA) – Globe Newswire
-
XORTX Welcomes New Member to the Board of Directors
-
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
-
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
-
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
-
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
-
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
-
Gamida Cell Actively Pursuing Strategic Alternatives
-
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
-
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
-
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
-
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
-
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
-
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Gamida Cell to Report Third Quarter 2023 Financial Results
-
MediWound Announces CEO Transition
Back to GMDA Stock Lookup
